MiNK Therapeutics Inc. (INKT)
MiNK Therapeutics Statistics
Share Statistics
MiNK Therapeutics has 3.96M shares outstanding. The number of shares has increased by 13.98% in one year.
| Shares Outstanding | 3.96M |
| Shares Change (YoY) | 13.98% |
| Shares Change (QoQ) | 0.03% |
| Owned by Institutions (%) | 2.14% |
| Shares Floating | 1.01M |
| Failed to Deliver (FTD) Shares | 1.34K |
| FTD / Avg. Volume | 3.96% |
Short Selling Information
The latest short interest is 51.73K, so 0.13% of the outstanding shares have been sold short.
| Short Interest | 51.73K |
| Short % of Shares Out | 0.13% |
| Short % of Float | 5.18% |
| Short Ratio (days to cover) | 1.1 |
Valuation Ratios
The PE ratio is -16.37 and the forward PE ratio is -2.04. MiNK Therapeutics's PEG ratio is 1.35.
| PE Ratio | -16.37 |
| Forward PE | -2.04 |
| PS Ratio | 0 |
| Forward PS | 1.1 |
| PB Ratio | -20.36 |
| P/FCF Ratio | -23.22 |
| PEG Ratio | 1.35 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for MiNK Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.32, with a Debt / Equity ratio of 0.
| Current Ratio | 0.32 |
| Quick Ratio | 0.32 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 1.24% and return on capital (ROIC) is 126.95%.
| Return on Equity (ROE) | 1.24% |
| Return on Assets (ROA) | -4.93% |
| Return on Capital (ROIC) | 126.95% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-724,447.06 |
| Employee Count | 31 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -5.16% in the last 52 weeks. The beta is 0.17, so MiNK Therapeutics's price volatility has been higher than the market average.
| Beta | 0.17 |
| 52-Week Price Change | -5.16% |
| 50-Day Moving Average | 9.97 |
| 200-Day Moving Average | 8.67 |
| Relative Strength Index (RSI) | 48.06 |
| Average Volume (20 Days) | 33.99K |
Income Statement
| Revenue | n/a |
| Gross Profit | -204.62K |
| Operating Income | -22.92M |
| Net Income | -22.46M |
| EBITDA | -22.25M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.65 |
Balance Sheet
The company has 3.37M in cash and 0 in debt, giving a net cash position of 3.37M.
| Cash & Cash Equivalents | 3.37M |
| Total Debt | 0 |
| Net Cash | 3.37M |
| Retained Earnings | -133.4M |
| Total Assets | 7.37M |
| Working Capital | -823.77K |
Cash Flow
In the last 12 months, operating cash flow was -15.76M and capital expenditures -73.56K, giving a free cash flow of -15.84M.
| Operating Cash Flow | -15.76M |
| Capital Expenditures | -73.56K |
| Free Cash Flow | -15.84M |
| FCF Per Share | -0.46 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
INKT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -7.21% |
| FCF Yield | -44.35% |
Analyst Forecast
The average price target for INKT is $19.5, which is 116.4% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $19.5 |
| Price Target Difference | 116.4% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Jan 28, 2025. It was a backward split with a ratio of 1:10.
| Last Split Date | Jan 28, 2025 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -28496.6 |
| Piotroski F-Score | 2 |